Yuan Zhou

Yuan Zhou inquired about the continuous distribution policy for organ allocation, specifically asking about the timeline for hearts and livers, stakeholders' potential concerns, and why lungs were approved earlier than other organs. Additionally, Zhou asked about the highest value and margin services within Strata's transplant value chain and the percentage of customers utilizing their full-service portfolio. A follow-up question focused on whether Strata's radiopharmaceutical pilot program primarily supports radiotherapeutics or radioimaging agents, and commercial products versus clinical trials.

Answer

Co-CEO and CFO Will Heyburn explained that continuous distribution remains the goal for all organs, with lungs already transitioned. He noted a deprioritization for hearts and livers due to regulatory focus on other pressing issues, with no certain timeline for their transition but an expected six-month comment period and gradual implementation. Heyburn clarified that while there isn't direct opposition, some stakeholders want to ensure readiness for the logistical challenges of a national organ allocation program. Regarding the transplant value chain, Heyburn stated that logistics and clinical segments have similar blended profit margins, with transplant clinical services showing slightly higher margins than non-transplant clinical. He highlighted that 40% of sequential logistics revenue growth in Q4 came from clinical customers leveraging integrated offerings for cost savings and convenience. For radiopharmaceuticals, Heyburn indicated that Strata's existing fleet is best suited for clinical trials due to smaller load capacities, though full cargo loads could be supported with further investment.